Kyung Chu on Treating Different Subtypes of the KRAS Mutation

Video

Kyung Chu, RN, NYU Langone Perlmutter Cancer Center, discusses treating patients with different subtypes of KRAS mutation.

Kyung Chu, RN, NYU Langone Perlmutter Cancer Center, discusses treating patients with different subtypes of KRAS mutation.

Typically, EGFR inhibitors are used in lung and colon cancer to treat patients with KRAS mutations. However, this therapy has mixed clinical outcomes for the patients, varying by their mutation subtype. Chu emphasizes that nurses and doctors must use the EGFR inhibitors wisely, and consider the patient’s subtype when deciding on a treatment plan.

Newsletter

Stay up to date on recent advances in oncology nursing and patient care.

Subscribe Now!
Recent Videos
Photo of a woman with blonde hair wearing a denim jacket in front of a blue background
2 experts are featured in this series.
2 experts are featured in this series.
Photo of a woman with brown hair and a floral blouse
Photo of a woman with a blue border around the image
2 experts are featured in this series.
2 experts are featured in this series.
Image of a woman with gray hair and glasses in front of a blue Oncology Nursing News background
Photo of a woman with blond wavy hair wearing a blazer in front of a blue Oncology Nursing News background
Photo of a woman with shoulder-length blond hair in front of an Oncology Nursing News backdrop
Related Content
pancreatic ductal adenocarcinoma

Proactive Management of NALIRIFOX-Related Diarrhea Is Crucial in Metastatic PDAC

Ashley Chan
April 12th 2025
Article

Assessing the signs and symptoms of chemotherapy-induced diarrhea and providing accurate and timely patient education may reduce complications and optimize survival outcomes.

The Vitals

Nicole Gay Shares How She Counsels Patients on Lung Cancer Screenings

Lindsay Fischer
November 15th 2023
Podcast

Nicole Gay, APRN-C, shares how nurse navigators can talk to their patients about lung cancer screening.

Digital rendering of lungs on a dark blue background

First-Line Amivantamab With Lazertinib Boosts OS in EGFR-Mutated NSCLC

Kristi Rosa
April 3rd 2025
Article

The combination of amivantamab and Lazertinib improved long-term survival over osimertinib in patients with EGFR-mutated non-small cell lung cancer.

The Vitals

ctDNA Monitoring is a Piece of the Puzzle in CRC Treatment

Lindsay Fischer
October 31st 2023
Podcast

Holly Chitwood, DNP, FNP-C, AGACNP-BC, explains how circulating tumor DNA monitoring helps providers screen minimal residual disease in individuals with colorectal cancer.

Line illustration of lungs on a cornflower blue background

Osimertinib Sustains OS Improvement in EGFR-Mutant NSCLC

Roman Fabbricatore
March 31st 2025
Article

Osimertinib monotherapy and combination treatment had safety profiles consistent with previous data on use of the drug in EGFR-mutated NSCLC.

Graphic reading "FDA APPROVED" resembling a stamp of approval

Cabozantinib Approved for Unresectable, Advanced/Metastatic epNET and pNET

Bridget Hoyt
March 26th 2025
Article

The FDA approved cabozantinib for use in patients with previously treated unresectable, locally advanced or metastatic, well-differentiated epNETs or pNETs.